Latest news in cancer
Kite completes acquisition of Tmunity
Press Release Feb 2023: – Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire...
High CR rates are overcome by CD22-directed CAR T-Cell therapy against CD19 relapse in LBCL
In February 2023, a phase 1 trial at a single institution found that it was safe and possible for people with heavily pretreated large B-cell lymphoma (LBCL)...
CAR T-cell treatment provides significant remission rates in clinical trials
Feb 2023: In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for triple-class exposed multiple...
Novel treatment target for lymphoma patients who relapse after CAR-T therapy
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell...
CT103A, CAR T-cell Therapy, has been designated as an orphan drug by the FDA
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics...
CAR T-cell treatment from IASO Biotherapeutics receives new FDA approval
Feb 2023: IASO Biotherapeutics’ investigational CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), CT103A, has received fast track...
Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer
Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or...
Sacituzumab govitecan-hziy is approved by FDA for HR-positive breast cancer
Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor...
Elacestrant is approved by FDA for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced...
Accelerated approval is granted by FDA to pirtobrutinib for relapsed or refractory mantle cell lymphoma
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN...
Pembrolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer
Feb 2023: For stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda,...
Zanubrutinib is approved by FDA for chronic lymphocytic leukemia or small lymphocytic lymphoma
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.